Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04432246
Other study ID # SMHC-OCD-007
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 11, 2020
Est. completion date August 30, 2022

Study information

Verified date September 2022
Source Shanghai Mental Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study used electroencephalogram (EEG) to predict the efficacy of repetitive transcranial magnetic stimulation (rTMS) in patients with obsessive-compulsive disorder.


Description:

Repetitive Transcranial Magnetic Stimulation (rTMS), as a relatively mature non-invasive neuromodulation technology, has been recommended for the treatment of patients with refractory OCD in multinational guidelines. However, due to the treatment setting and the patient's feature, nearly half of the patients have no significant changes after rTMS treatment. In order to better predict the outcome of rTMS and improve the treatment efficiency, this project intends to look for markers that have a predictive effect at baseline or early treatment. Electroencephalogram (EEG) is a cheap and fast method that usually occurs before the symptoms change, thus it is possible to determine whether the patient has responded to the intervention. In this project, the supplementary motor area (SMA) is selected as the stimulation target. The individual head magnetic resonance image positioning and navigation and rTMS compatible real-time EEG acquisition technology are used to monitor the resting state of EEG and rTMS single pulse stimulation and changes in neural networks before and after treatment. This is a preliminary exploration looking for effective predictive indicators of efficacy in EEG and the relationship between EEG and symptoms changes. In order to lay the foundation for further research and guide clinical treatment.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 30, 2022
Est. primary completion date July 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - age>18 years old; - DSM-5 criteria for OCD; - Y-BOCS total score > or = 16 ->or=9 yrs education Exclusion Criteria: - any additional current psychiatric comorbidity, except for obsessive-compulsive personality disorder serious suicide risk; - the inability to receive rTMS because of metallic implants, or history of seizures,or history of head injury, or history of neurosurgery; - any major medical disease; - pregnancy or nursing of an infant; - participation in current clinical study; - current use of any investigational drug; - TMS/DBS treatment at any point in their lifetime; - history of long-time use of benzodiazepines

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Continuous theta burst stimulation (cTBS)
50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) It assesses the severity of OCD symptoms. The Y-BOCS scale ranges from 0 to 40, with 0 being no symptoms and 40 being severe.The responder on Y-BOCS is defined as a Y-BOCS decrease at least 35% from the baseline at post-treatment. Up to 6 months
Primary EEG biomarkers as predictors of response to rTMS TMS-EEG and resting state EEG will be performed to investigate predictors of response to rTMS in OCD patients. The a, ß and d band power in resting state in each brain area of OCD patients will be recorded and analyzed. Also, in TMS treatment, event related potentials (ERPs) including motor evoked potentials (MEPs) amplitude, I waves, a band power and ß band power will be analyzed. baseline
Secondary Change in The Beck Depression Inventory (BDI) It consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression symptoms. Up to 6 months
Secondary Change in The Beck Anxiety Inventory (BAI) It is an inventory of anxiety symptoms with 18 items that are rated on a 5-point Likert scale(0 to 4). Total scores range from 0 to 72, with higher scores indicating more severe anxiety symptoms. Up to 6 months
Secondary Change in The Perceived Stress Scale(PSS) The Perceived Stress Scale (PSS) has 10 items to assess stress status within four weeks. Items are classified into five levels, from 0 (never) to 4 (very often). Total scores range from 0 to 40. The higher the total score, the stronger the level of stress the patient feels. Up to 6 months
Secondary Change in Pittsburgh sleep quality index(PSQI) The Pittsburgh Sleep Quality Index (PSQI) contains 19 self-rated questions which measures seven aspects of sleep: (1) subjective sleep quality, (2) sleep latency, (3) sleep duration, (4) habitual sleep efficiency, (5) sleep disturbances, (6) use of sleeping medication, and (7) daytime dysfunction. The 19 self-rated items are combined to form seven component scores, each of which has a range of 0-3 points (0 indicates no difficulty, while 3 indicates severe difficulty). The seven component scores are then summed to yield one global score, with a range of 0-21 points (0 indicating no difficulty, and 21 indicating severe difficulties in all the seven areas of sleep quality). Up to 6 months
Secondary Change in Obsessive Compulsive Inventory-Revised(OCI-R) It is an inventory of OCD symptoms with 18 items that are rated on a 5-point Likert scale. Total scores range from 0 to 72, with higher scores indicating more severe OCD symptoms. Up to 6 months
Secondary Change in Side-effect questionnaire It consists of 10-item and uses 0 to 3 severity scale to rate the intensity of side effects. Total scores range from 0 to 30, with higher scores indicating more severe side-effect. It also assesses the relation between side-effect and the effects of rTMS using 0 to 4 scale. Total scores range from 0 to 40, with higher score indicating the greater relation. Up to 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02886780 - "Concentrated Exposure Treatment" (cET) for for Obsessive Compulsive Disorder N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Recruiting NCT05240924 - ERP to Improve Functioning in Veterans With OCD N/A
Completed NCT03476902 - Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD N/A
Completed NCT01617083 - Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Phase 2
Completed NCT01447966 - Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder N/A
Recruiting NCT02528331 - Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study N/A
Not yet recruiting NCT02160431 - Neuropsychological Profiles of Pediatric Obsessive Compulsive Disorder (OCD) N/A
Completed NCT02656784 - The Efficacy of TBCT Compared to ERP in the Treatment of OCD Patients, by the Assessment of Magnetic Resonance. N/A
Recruiting NCT01879254 - Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD). N/A
Completed NCT00216294 - Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder Phase 2
Active, not recruiting NCT02216981 - Examining the Feasibility and Acceptability of Good Quality Intensive CBT for OCD and Good Quality Weekly CBT for OCD N/A
Recruiting NCT05160129 - Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder N/A